Christopher Roybal, MD
Ophthalmology · Albuquerque, NMNPI 1639375397
Payments from drug & device makers
Across 202 payments — averaging $287.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- Genentech USA, Inc.$13K
- Regeneron$7K
- Genentech, Inc.$7K
- Carl Zeiss Meditec USA, Inc.$3K
- Alcon$690
- plus $2K from 17 others
What the payments were for
- Consulting fees$17,30534%
- Speaking & faculty fees$23,51946%
- Travel & lodging$4,4409%
- Food & beverage$5,58311%
- Education$2290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $25,060 |
| Genentech USA, Inc. | 71 | $13,045 |
| Regeneron | 2 | $7,069 |
| Genentech, Inc. | 4 | $7,014 |
| Carl Zeiss Meditec USA, Inc. | 3 | $2,866 |
| Alcon | 17 | $690 |
| Regeneron Healthcare Solutions, Inc. | 14 | $552 |
| Alimera Sciences, Inc. | 1 | $373 |
| Apellis Pharmaceuticals, Inc. | 10 | $358 |
| Notal Vision, Inc. | 2 | $269 |
| Astellas Pharma US Inc | 7 | $212 |
| Sun Pharmaceutical Industries Inc. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 5 | $105 |
| Eyepoint US, Inc. | 5 | $87 |
| Novartis | 3 | $55 |
| Coherus Oncology, Inc. | 2 | $47 |
| Biogen | 1 | $27 |
| Harrow Eye, LLC | 1 | $23 |
| Alcon Research LLC | 1 | $21 |
| Abbott | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$23,083
- VABYSMO$14,545
- SUSVIMO$4,051
- ATLAS 500$2,800
- CIRRUS 6000 with AngioPlex$2,800
- CIRRUS HD-OCT$2,800
- CLARUS$2,800
- YUTIQ$373
- Iluvien$373
- Constellation$339
- CEQUA$125
- EYLEA HD$122
- Syfovre$122
- EYLEA$120
How this compares
$58,076 in reported general payments places this provider in the 90th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 224 | $7,055 |
| Ofloxacin | 158 | $1,885 |
| Latanoprost | 138 | $1,485 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 57 | $1,091 |
| Ketorolac Tromethamine | 25 | $784 |
| Timolol Maleate | 41 | $772 |
| Brimonidine Tartrate | 31 | $486 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Albuquerque
- John PitcherAlbuquerque$2.6M
- Robert MelendezAlbuquerque$766K
- Mark ChiuAlbuquerque$736K
- Arup DasAlbuquerque$449K
- Frank MaresAlbuquerque$117K
- Iuri GolubevAlbuquerque$62K
- Barbara MarshAlbuquerque$53K
- Stephen ColemanAlbuquerque$48K
- Kenneth HimmelAlbuquerque$21K
- Gregory OgawaAlbuquerque$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.